Skip to main content

Dr. Mary Tagliaferri

Equibles does not estimate personal net worth.

Get an email with a short summary when Nektar Therapeutics publishes a filing, an earnings call transcript or a press release.

Get NKTR alerts

About Dr. Mary Tagliaferri

Dr. Mary Tagliaferri has spoken on 3 earnings calls and 2 other investor events across 1 company, most recently for Nektar Therapeutics on November 12, 2026. Nektar Therapeutics is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Nektar Therapeutics includes Howard Robin (CEO), Jillian Thomsen (CFO and Chief Accounting Officer), Linda Rubinstein (CFO) and 2 others.

Dr. Mary Tagliaferri on recent calls

“As stated earlier, we had a significant presence at the EADV conference with three separate oral sessions for RESPEG. We had two presentations for Resolve-AD.”
Other, Nektar Therapeutics Q3 2026 Financial Results ·
“At Nectar, our strategy has been to advance a first-in-class regulatory T-cell, or T-REG, mechanism to address the underlying biology of autoimmune and inflammatory diseases.”
Other, Analyst and Investor Event at EADV ·
“So as you know, we have a 24-week follow-up off-treatment period in the Resolve AA study. This is an ongoing part of our trial, and in the fourth quarter, we will have the data.”
Other, Nektar Therapeutics Q2 FY2026 Earnings Call ·
“We right now are activating sites, and we have the final protocol written. In terms of sites, remember in the Resolve AD phase two, we enrolled 17% of the patients from the United States and 28% from North America, and we had 67% of the patients came from Europe and 5% from Australia.”
Other, Nektar Therapeutics Q1 FY2026 Earnings Call ·
“Thank you, Jay-Z. Before we dive into the findings, I'd like to briefly review the clinical trial design. As a reminder, our Phase IIb Resolve AA trial enrolled 92 adult patients with severe to very severe alopecia areata.”
Other, Analyst and Investor Event with Alopecia Areata Experts ·

Affiliation history

Company network

Leadership on record at Nektar Therapeutics

Recent activity